# Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Source: https://onco.cc/trials/nct06384560/  
OnCo record `nct06384560` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pembrolizumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Amsterdam UMC, location VUmc, now recruiting.

## Summary

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) is a phase 1/2, interventional study registered as NCT06384560 by Amsterdam UMC, location VUmc, with a registry enrolment figure of 66 participants, started 2024-09-23 and due to reach its primary completion in 2028-03. Interventions recorded: Pembrolizumab; Folfirinox; SABR. Conditions listed: Localized Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma. Primary outcome: 1-year progression-free survival rate. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the pancreas (WHO VI or VII)". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PREOPANC-5
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06384560
- Phase: 1/2
- Setting: Neoadjuvant Triple Treatment With mFOLFIRINOX, Pembrolizumab and SABR in Patients With (Borderline) Resectable Pancreatic Cancer (PREOPANC-5): a Multicenter Single Arm Phase Ib/II Trial of the Dutch Pancreatic Cancer Group
- Sponsor: Amsterdam UMC, location VUmc
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT06384560: https://clinicaltrials.gov/study/NCT06384560

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06384560.json